This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • ALECENSA®▼(alectinib)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼ (pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozlytrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Haematology
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • Evrysdi®▼ (risdiplam)
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab) [Great Britain]
      • Avastin (bevacizumab) [Northern Ireland]
      • Evrysdi®▼(risdiplam)
      • GAZYVARO® (obinutuzumab) Great Britain
      • GAZYVARO® (obinutuzumab) Northern Ireland
      • HEMLIBRA®▼(emicizumab) Great Britain
      • HEMLIBRA®▼(emicizumab) Northern Ireland
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab) GB
      • OCREVUS®▼ (ocrelizumab) NI
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • Rozlytrek® ▼(entrectinib)
      • TECENTRIQ®▼ (atezolizumab) Great Britain
      • Tecentriq®▼ (atezolizumab) Northern Ireland
    • Adverse Event Reporting
      Adverse Event Reporting Overview
    • Home
    • Roche Medicines
      • Oncology
        • ALECENSA®▼(alectinib)
        • Kadcyla® (trastuzumab emtansine)
        • PERJETA® (pertuzumab)
        • PHESGO®▼ (pertuzumab/trastuzumab)
        • TECENTRIQ®▼ (atezolizumab)
        • Rozlytrek▼(entrectinib)
      • Neuroscience
        • OCREVUS®▼ (ocrelizumab)
      • Haematology
        • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
        • Evrysdi®▼ (risdiplam)
        • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      • Oncology
        • Breast Cancer
      • Haematology
        • Haematology
      • Neuroscience
        • Neuroscience
    • Congress and Meetings
    • HCP Materials
    • FAQs
    • Prescribing Information
      • Find out more about:
        • ALECENSA®▼(alectinib)
        • Avastin® (bevacizumab) [Great Britain]
        • Avastin (bevacizumab) [Northern Ireland]
        • Evrysdi®▼(risdiplam)
        • GAZYVARO® (obinutuzumab) Great Britain
        • GAZYVARO® (obinutuzumab) Northern Ireland
        • HEMLIBRA®▼(emicizumab) Great Britain
        • HEMLIBRA®▼(emicizumab) Northern Ireland
        • Herceptin® (trastuzumab) IV
        • Herceptin® (trastuzumab) SC
        • Kadcyla® (trastuzumab emtansine)
        • OCREVUS®▼ (ocrelizumab) GB
        • OCREVUS®▼ (ocrelizumab) NI
        • Perjeta® (pertuzumab)
        • Phesgo®▼(pertuzumab/trastuzumab)
        • Polivy®▼(polatuzumab vedotin)
        • Rozlytrek® ▼(entrectinib)
        • TECENTRIQ®▼ (atezolizumab) Great Britain
        • Tecentriq®▼ (atezolizumab) Northern Ireland
    • Adverse Event Reporting
    • Sign in
    • Logout
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.


    You are here:

    1. Resources
    2. Congresses and Meetings

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

    Prescribing Information OCREVUS®▼(ocrelizumab) Great Britain
    Prescribing Information OCREVUS®▼(ocrelizumab) Northern Ireland

    Adverse event reporting and additional monitoring

    Congress Highlights

    • ECTRIMS 2021 Virtual Congress Highlights

      25.03.2022

      ECTRIMS 2021 Virtual Congress

      Listen to conversations from our eminent panel of clinicians discussing highlights from the congress.

      More
    • ASH 2021

      27.01.2022

      ASH 2021

      Learn more about the key haematology data highlights presented at the ASH 2021 congress and how they could impact UK clinical practice.

      More
    • SABCS 2021

      20.01.2022

      SABCS 2021

      Learn more about the key data highlights presented at the 2021 San Antonio Breast Cancer Symposium.

      More
    • 2021 Annual US Oncology Meeting 2021 image

      03.09.2021

      Annual US Oncology Meeting 2021 (#ASCO2021)

      Learn more about the key breast cancer data highlights presented at the 2021 Annual US Oncology Meeting.

      More
    • 13.12.2021

      ASH 2020

      Learn more about the key haematology data highlights presented at the virtual edition of the ASH 2020 congress and how they could impact UK clinical practice.

      More
    • ABN Virtual Meeting 2020

      06.12.2021

      ABN 2020

      Take a look at the Roche data presented at virtual ABN 2020.

      More

    Roche Organised Meetings & Sponsored Symposia

    • Virtual Meeting

      09.05.2022

      Virtual Lung Cancer Expert Forum

      These presentations explore the management of metastatic non-small cell lung cancer (mNSCLC) and extensive stage small cell lung cancer (ES-SCLC) in which our speakers share their expertise.

      More
    • NGBC Next Generation Breast Cancer

      19.11.2021

      Next Generation: Breast Cancer 2021

      Highlights from the Next Generation Breast Cancer 2021 meeting, which aims to unite and educate breast cancer Specialist Registrars and early Consultants from across medical disciplines.

      More
    • COVID-19 in OCREVUS®▼(ocrelizumab) treated patients - the story so far.

      05.10.2021

      COVID-19 in OCREVUS®▼(ocrelizumab) treated patients - the story so far.

      Watch the recording of our COVID-19 in OCREVUS®▼(ocrelizumab) treated patients - the story so far webinar.

      More
    • BSH 2021 Symposium

      25.10.2021

      BSH 2021

      Watch the recording of our symposium from BSH on “Optimising the treatment pathway for patients with relapsed/refractory diffuse large B-cell lymphoma".

      More
    • Future Positive Lite

      09.11.2021

      Future Positive Lite - November 2020

      Learn about how to tailor treatment for patients with HER2-positive early breast cancer from UK experts.

      More
    • 11.02.2022

      Multiple Sclerosis: impact of COVID-19 and vaccination

      Watch the recording of our Multiple Sclerosis: impact of COVID-19 and vaccination webinar.

      More
    • 08.12.2021

      Virtual Liver Cancer Expert Forum

      Learn about the latest developments in the treatment of HCC presented at the Roche organised LiCEF 2021 virtual meetings.

      More

     




    M-GB-00006380

    Date of preparation: March 2022

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2022 Roche Products Limited
    • 04.04.2022
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00006977 Date of Preparation April 2022.